Perbak Capital Partners LLP Regeneron Pharmaceuticals, Inc. Transaction History
Perbak Capital Partners LLP
- $338 Billion
- Q2 2024
A detailed history of Perbak Capital Partners LLP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Perbak Capital Partners LLP holds 650 shares of REGN stock, worth $530,822. This represents 0.2% of its overall portfolio holdings.
Number of Shares
650Holding current value
$530,822% of portfolio
0.2%Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,490Shares Held
85.8MCall Options Held
908KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$7.34 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.9 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$6.76 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$3.95 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$3.79 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $87.5B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...